Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Aurrigo flags strong growth in autonomous division

(Sharecast News) - Aurrigo International flagged strong growth in its autonomous division in an update on Tuesday, with 2024 revenue rising 433% to £2.9m, up from £0.5m in the prior year. The AIM-traded firm said total revenue for the year was expected to be £8.9m, in line with expectations, while an adjusted EBITDA loss of £1.9m was ahead of forecasts.

Loss before tax was also anticipated to be better than expected.

The company said its automotive division was continuing to provide stable cash flow, generating £5.9m in revenue, slightly lower than the £6.1m recorded in 2023.

At year-end, Aurrigo had net cash of £3m, and with the completion of a funding round in January, the company said it was well positioned to support its next phase of growth.

"The 2024 financial year was another significant year of success for Aurrigo," said chief executive officer David Keene.

"The team has worked tirelessly to drive growth and deliver best in class services and solutions for our customers."

Keene said the strong growth seen in the autonomous division reflected the demand for the company's smart airside solutions as airports looked to reduce costs and emissions while improving efficiency.

"With an expanding partner network and healthy sales pipeline, we look ahead to further autonomous growth, supported by our automotive division."

Aurrigo said it was planning to release its audited results for the year in May.

At 1100 GMT, shares in Aurrigo International were down 1.05% at 47p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.